Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx-To-OTC Switches "Not In Financial Interests" Of Manufacturers - Juhl

This article was originally published in The Tan Sheet

Executive Summary

Three years of market exclusivity following an Rx-to-OTC switch might not be enough of an incentive to encourage manufacturers to apply for switches, former FDA Nonprescription Drugs Advisory Committee chair Randy Juhl, PhD, University of Pittsburgh, suggested at the American Pharmaceutical Association annual meeting March 11.
Advertisement

Related Content

Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
Prilosec OTC “Coverage Gap” Pitch Spotlights Medicare Payment Question
OTC Cholesterol Drugs May Be Revisited By FDA In 2000
OTC Cholesterol Drugs May Be Revisited By FDA In 2000

Topics

Advertisement
UsernamePublicRestriction

Register

PS091003

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel